1. Introduction {#sec1}
===============

Neoadjuvant chemotherapy (NAC) is widely used in locally advanced breast cancer (BC) treatment. It is increasingly used in women with early stage disease \[[@B1]\]. It allows the clinicians to observe tumor response and modify radiotherapy plan \[[@B2]\]. Adjuvant therapeutic strategies for patients who underwent NAC do not differ substantially from patients treated with upfront surgery \[[@B3]--[@B6]\]; nevertheless, the role of postmastectomy radiotherapy (PMRT) after NAC is strongly debated. Moreover there is a lack of prospective trials in this treatment setting.

In an era of "tailored treatment," additional data are needed for patients who receive this treatment sequence to determine which subsets of patients can benefit from radiation \[[@B7]\].

The aim of our analysis was to identify major prognostic factors in a single-center series of advanced BC patients receiving NAC, with emphasis on the role of PMRT.

2. Materials and Methods {#sec2}
========================

2.1. Patient Population {#sec2.1}
-----------------------

From 1997 to 2011, 226 patients were treated with NAC and mastectomy at the University of Florence Radiotherapy Unit (Florence, Italy). Previous solid tumors, age less than 18, and BC recurrences or contralateral tumor were considered exclusion criteria of the study. To minimize bias, all patients with disease recurrence within 2 months after surgery, completion of adjuvant chemotherapy, and a minimum follow-up period shorter than 6 months were excluded from analysis. We retrospectively reviewed a series of 170 BC patients who received NAC and mastectomy; 98 cases (57.6%) underwent PMRT and 72 cases (42.4%) did not receive radiation. Informed consent was obtained from all patients.

In our multidisciplinary team, specialized expert pathologists, dedicated to BC specimens\' evaluation, perform pathology assessment. Estrogen receptor (ER) status, progesterone receptor (PgR) status, and Ki-67 labeling index determined with the MIB1 monoclonal antibody were assessed. For ER and PgR status two categories (negative/positive) were considered according to well-established cut-off values \[[@B8]\]. HER2 immunohistochemistry (IHC) scores of 0 and 1+ were considered negative. HER2 IHC 3+ and fluorescent in situ hybridization (FISH)---amplified tumors, were considered positive. All IHC 2+ tumors were tested for gene amplification by FISH. The applied well-validated \[[@B9]\] primary antibodies for evaluating ER and PgR in BC by IHC have been extensively described in earlier published reports \[[@B10], [@B11]\].

BC was classified according to the histological type and the AJCC TNM classification of malignant tumors. Concerning Ki-67, we used a validated \[[@B12]\] cut-off value of 20% to distinguish Ki-67 high from Ki-67 low, although the ideal threshold has not been identified yet and varies widely from 1 to 28.6% \[[@B13]\].

2.2. Treatment Details {#sec2.2}
----------------------

All patients, except 8 cases, received anthracyclines as part of a combination chemotherapy regimen (98.8%), with 69 patients (40.6%) also receiving a taxane. Concerning HER2 status, 23 patients had HER2 positive and 45 patients had HER2 negative status at pathological specimen; in 102 cases HER2 status was undetermined or missing. None of these patients were treated with neoadjuvant or adjuvant trastuzumab, since they were treated before 2006.

Most commonly administered chemotherapy regimens were FEC and ET; FEC chemotherapy consisted of 500 mg/m^2^ 5-fluorouracil, 75 mg/m^2^ epirubicin, and 500 mg/m^2^ cyclophosphamide, given on day 1. The ET regimen consisted of 75 mg/m^2^ epirubicin and 75 mg/m^2^ docetaxel, given on day 1. The median number of chemotherapy cycles received was 4 (mean, 4.7; range, 2--6).

Additionally, 108 patients (88.2%) received adjuvant hormonal therapy: tamoxifen for 5 years (*n* = 63; 37.1%), aromatase inhibitors for 5 years (*n* = 52; 30.6%), and tamoxifen for 2 years and then shift to aromatase inhibitors (*n* = 35; 20.5%).

Concerning PMRT, the treatment volumes typically included the chest wall and draining lymphatics (*n* = 84; 85.7%), consisting in the supraclavicular (SCV) and infraclavicular (ICV) nodal region (total dose 50 Gy; 2 Gy daily fractions), with mixed photon and electron beams technique, chosen at physician discretion. In our Institute we did not irradiate mammary internal nodal region, unless pathologically involved. In selected cases (*n* = 14; 14.3%) only chest wall was irradiated.

Patients underwent a treatment-planning noncontrast CT scan. Concerning CTV identification, for chest wall volume, the cranial limit was the caudal border of the clavicular head, the caudal limit was the contralateral inframammary fold, the lateral limit was the midaxillary line, and the medial limit was the sterna-rib junction. For SCV nodes the cranial limit was a line passing below the cricoid cartilage, the caudal limit was the caudal edge of the clavicular head, the anterior limit was the poster edge of the sternocleidomastoid (SCM) muscle, the posterior limit was the anterior aspect of the scalene muscle, the lateral limit was the lateral edge of the SCM muscle cranially, and the junction first rib-clavicle caudally, and the medial limit was a line excluding thyroid and trachea. For ICV nodes, the cranial limit was pectoralis minor muscle insert on coracoid, the caudal limit was axillary vessels cross-medial edge of pectoralis minor muscle, the anterior limit was the posterior surface of pectoralis major muscle, the posterior limit was ribs and intercostal muscles, the lateral limit was the medial border of pectoralis minor muscle, and the medial limit was the thoracic inlet.

2.3. Statistical Analysis {#sec2.3}
-------------------------

For the survival analysis, the date of histological BC diagnosis was used as the start of observation. The survival time was calculated from the date of diagnosis to the date of death or the date of the last follow-up for living patients. We considered as events the deaths for all causes (overall survival, OS). We also estimated the disease-free survival (DFS) as the interval time from the date of diagnosis to the date of locoregional recurrence (LRR) or distant metastases (DM).

The actuarial rates of death, LRR, or DM were calculated according to the Kaplan-Meier method, and comparisons were made using the log-rank test. Estimated relative risk of death, LRR, or DM were expressed as hazard ratios (HR) and their corresponding 95% confidence intervals (95% CI).

The clinical and pathologic factors that were statistically significant (two-tailed *P* \< 0.05) on univariate analysis of LRR, DM, or OS were included in a multivariate analysis using the Cox proportional hazards regression model. All statistical tests were performed by the SAS software (SAS for Windows, version 9.1).

In order to analyze if the concomitant presence of well-known \[[@B14]\] risk factors influences the LRR rate, we stratified the patients in three risk groups (0-1 factors versus 2 factors versus 3--5 factors). We considered the following risk features: skin/nipple involvement, SCV nodal involvement, no tamoxifen use, extracapsular extension (ECE), and ER negative disease.

3. Results {#sec3}
==========

3.1. Series Characteristics {#sec3.1}
---------------------------

The median age at BC diagnosis was 48.9 years (range 24--76). The median follow-up periods of all irradiated and nonirradiated cases were 7.2 and 6.7 years, respectively.

[Table 1](#tab1){ref-type="table"} showed major clinical characteristics of the whole series and stratified by radiation treatment. When compared with patients who did not receive PMRT, a larger number of irradiated patients had greater clinical and pathological T, N, and combined AJCC TNM stage (*P* ≤ 0.024 for all comparisons). There were no differences between the two groups considering age, histology, nuclear grade, lymph vascular invasion (LVI), downstaging after NAC based on pathological response, use of hormonal therapy, Ki-67 index, and percentage of ER and PgR.

3.2. Prognostic Factors of the Whole Series {#sec3.2}
-------------------------------------------

At a median follow-up period of 7.7 years (range 2--16; standard deviation (SD) 5.1), 98 patients are alive (57.6%) and 72 patients are dead (42.4%). Median time to LRR (*n* = 26) was 3.3 years (range 0.7--14.6; SD 3.9); median time to DM (*n* = 86) was 3.0 years (range 0.7--12.4; SD 2.6). The 5-year and 10-year actuarial LRR rate were 14.5% and 15.9%, respectively.

The majority of LRR failures occurred on the chest wall (*n* = 15; 57.7%). SCV was the first nodal site of relapse in 7 cases (26.9%). Axillary (*n* = 2), infraclavicular (*n* = 1), and internal mammary nodal regions (*n* = 1) were rare sites of LRR (15.4%).

[Table 2](#tab2){ref-type="table"} showed LRR, DM, and OS rates according to main clinical features. In [Table 3](#tab3){ref-type="table"} survival rates were summarized according to major pathologic characteristics.

The factors that significantly correlated with poor LRR outcome were clinical N2 tumors, pathologic skin involvement, LVI, and the presence of ECE. The factors that significantly correlated with poor DM outcome were clinical N2 tumors, pN2, pN3 tumors, LVI, and ECE. Concerning OS, the significant protective features were pT1 tumors and ER positive status, while pN1, pN2, pN3 tumors, and ECE were unfavorable risk factors.

In the multivariate Cox regression analysis no factors were independently associated with LRR. The multivariate analysis of distant metastases occurrence and overall survival are described in [Table 4](#tab4){ref-type="table"}. The factors that significantly correlated with survival outcome were ≥4 positive nodes, ECE, and estrogen receptor positive disease.

The LRR rate for the 61 patients (35.9%) with one or none of selected \[[@B14]\] risk factors (6 events) was 10.9%, the 75 patients (44.1%) with two factors (10 events) had a rate of 24.5%, and the 34 patients (20%) with three or more factors (10 events) had a rate of 54.3% (log rank test *P* = 0.023; [Figure 1](#fig1){ref-type="fig"}). In an analysis stratified by radiation use, PMRT showed a protective effect (*P* = 0.029).

3.3. Locoregional Recurrence Rate according to Use of Postmastectomy Radiotherapy {#sec3.3}
---------------------------------------------------------------------------------

In [Table 5](#tab5){ref-type="table"} the impact of PMRT on LRR for various subgroups of patients is shown.

PMRT was associated with reduced LRR for patient with clinical T3 staged disease (16.7% versus 38.7%; *P* = 0.015; [Figure 2](#fig2){ref-type="fig"}). For patients with clinical T4 and clinical N2 and N3 tumors, no difference in LRR rates was observed. Also concerning pathological features, no difference in LRR rates was observed. In addition, in the subset of patients that achieved complete response after NAC (pCR; *P* = 0.29) or downstaging (*P* = 0.68), no statistical significance was evidenced.

3.4. Treatment Safety {#sec3.4}
---------------------

Major hematological and nonhematological side effects are summarized in [Table 6](#tab6){ref-type="table"}. The most represented hematological G3--G5 side effect was neutropenia (17%). The most frequent radiotherapy-related acute side effect was erythema (33%). At a median follow-up of 7.2 years, the most represented late RT-related side effect was fibrosis (20%).

4. Discussion {#sec4}
=============

The Danish and the British Columbia trials have established the survival advantage following radiotherapy in postmastectomy patients \[[@B15], [@B16]\]. The Early Breast Cancer Trialists\' Collaborative Group meta-analysis has demonstrated that PMRT, besides improving local control rates, confers an OS benefit \[[@B17]\]. On the basis of these studies and others, the role of the indication to PMRT has traditionally been determined by pathologic staging, with surgery as the first treatment modality \[[@B18], [@B19]\].

NAC is nowadays based on regimens containing anthracyclines, taxanes, and trastuzumab in case of HER2 positive disease. The toxicity profile of these drugs is well known, namely, characterized by potential cardiac \[[@B20]--[@B23]\] and pulmonary \[[@B24]--[@B26]\] adverse events. Although NAC has many advantages, its impact on surgical staging reduces the applicability of the traditional pathologic guidelines for PMRT.

Guidelines for the use of PMRT after NAC have not been established. Retrospective series have demonstrated that the omission of PMRT after NAC in high-risk patients can result in an unacceptable high rate of LRR, even in case of pathological complete response \[[@B7], [@B27]\]. For this reason, the role of PMRT is generally determined by clinical staging before NAC without regard for the response to NAC \[[@B18]\].

Risk factors for LRR in this specific setting are not well established. Advanced clinical or pathologic stage, triple-negative receptor status, and presence of LVI and/or ECE emerged as high-risk features that should warrant consideration of PMRT after NAC \[[@B28]\]. In our experience greater clinical nodal status, tumor stage, the presence of LVI, and nodal ECE emerged as adverse prognostic factors; these results are in line with many published series \[[@B7], [@B18], [@B28], [@B29]\].

Concerning age at diagnosis, Garg et al. \[[@B30]\] retrospectively analyzed 107 consecutive BC patients younger than 35 years with stage IIA--IIIC disease, treated with doxorubicin-based NAC and mastectomy, with or without PMRT. In this experience the use of PMRT led to a statistically greater rate of local control and OS compared with patients without PMRT.

Response to NAC is another debated issue in adjuvant PMRT decision-making. Data regarding LRR rates in patients who achieve a pCR are limited, although few data supported stage IIIA patients with pCR as being at low risk \[[@B28]\]. Concerning tumor biology and chemotherapy response, many experiences showed that residual disease after NAC seems to have a greater implication for outcome for those in whom systemic therapy would have been expected to produce a more favorable response, such as ER and HER2 positive patients \[[@B31]--[@B34]\].

Conversely, other studies suggested how PMRT should be indicated regardless of response to NAC \[[@B18], [@B35]\]. Also in our series disease downstaging and/or pCR to NAC were not independent prognostic factors for LRR occurrence.

In our experience PMRT was significantly protective only in case of clinical staged T3 tumors, regardless of response to NAC. Our results are consistent with the experience of M. D. Anderson Cancer Center, which in our knowledge represents the largest published series.

In a relevant study published in 2004, Huang et al. \[[@B7]\] showed how radiation was found to benefit both local control and survival for patients presenting with clinical T3 tumors or stage III-IV disease (ipsilateral SCV nodal) and for patients with four or more positive nodes.

In 2011, Nagar et al. \[[@B36]\] tried to determine the impact of PMRT after NAC on LRR in 162 patients with clinical T3N0 disease. PMRT was effective in reducing the LRR rate, even when there was no pathologic evidence of nodal involvement after NAC.

However we are aware of the limitations of our retrospective study: the two cohorts in the analyses had differences in several factors, and the more advanced tumor characteristics were in the PMRT group. PMRT may overcome negative pathologic features in the cohort.

A complex evaluation based on the presence of multiple risk factors should be of primary importance in the decision-making process for PMRT after NAC.

Fowble et al. \[[@B28]\] identified a cohort of women treated with NAC and mastectomy for whom PMRT may be omitted according to the projected risk of LRR. Seven breast cancer physicians from the University of California cancer centers created 14 hypothetical clinical case scenarios; an overall summary risk assessment table was developed, using the American College of Radiology rating scale. Clinical stage II (T1-2N0-1) patients, aged \> 40 years, with ER positive subtype, with pCR or 0--3 positive nodes without LVI or ECE, were identified as having \<10% risk of LRR without radiation.

Huang et al. \[[@B7], [@B14]\] retrospectively reviewed the hospital records of 542 patients treated on six consecutive institutional prospective trials using NAC and PMRT. In the multivariate analysis, skin/nipple involvement, SCV nodal involvement, no tamoxifen use, ECE, and ER negative were independently associated with developing LRR (HR 2.1--2.8; *P* \< 0.001--0.020). The 10-year rate of LRR for patients with one or none of these factors was only 4%, but patients with two factors had a rate of 8%, and patients with three or more factors had a rate of 28% (*P* \< 0.0001 for 0-1 factor versus 3--5 factors).

In order to validate the independent factors shown in the experience of the M. D. Anderson Cancer Center, we performed the same multiple factors analysis. Also in our series we found a significant higher LRR rate in patients with a greater number of risk factors (HR 2.70; 95% CI 1.12--6.53; *P* = 0.023; 54.3% LRR rate for patients with 3--5 factors).

The 2007 National Cancer Institute conference report recommended PMRT after NAC for patients presenting with clinical stage III disease or those with positive nodes after chemotherapy \[[@B37]\]. Our experience adds strength to the experiences that suggest PMRT after NAC based on clinical staging; however, we strongly believe that PMRT after NAC should be indicated following a comprehensive assessment of multiple factors.

5. Conclusions {#sec5}
==============

Our experience confirmed the impact of pathological nodal involvement in patients\' outcome. After NAC and mastectomy, PMRT was found to benefit local control of patients presenting with clinical T3 tumors, regardless of the response to chemotherapy. Radiation should always be considered after a careful multidisciplinary assessment of multiple risk factors. However prospective trials in properly selected patients are strongly needed.
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![Locoregional recurrence rates according to number of selected risk factors.](BMRI2014-719175.001){#fig1}

![Kaplan-Meier survival curve of locoregional recurrence for the cohort of patients with clinically T3 disease who received NAC and mastectomy. Patients were stratified by whether they received postmastectomy radiation (PMRT; *n* = 21) or not (No PMRT; *n* = 27). Statistical comparison between the survival curves was made using the log-rank test (*P* = 0.015).](BMRI2014-719175.002){#fig2}

###### 

Distribution of 170 breast cancer cases according to adjuvant radiotherapy.

  -----------------------------------------------------------------------------------
  Feature                             Total \     No PMRT \   PMRT \     *P* value°
                                      *n* = 170   *n* = 72    *n* = 98   
  ----------------------------------- ----------- ----------- ---------- ------------
  Age groups                                                              

   ≤40                                33          18          15          

   41--50                             62          25          37          

   51--60                             5           18          32          

   \>60                               25          11          14         0.40

  Clinical T classification                                               

   T1                                 4           2           2           

   T2                                 52          28          24          

   T3                                 48          27          21          

   T4                                 66          15          51         **0.002**

  Clinical N classification                                               

   N0                                 42          20          22          

   N1                                 95          45          50          

   N2                                 33          7           25         **0.024**

  Clinical stage                                                          

   IIA                                16          8           8           

   IIB                                51          32          19          

   IIIA                               35          17          18          

   IIIB                               63          15          48          

   IIIC                               3           ---         5          **0.0001**

  Multiple Foci                                                           

   No                                 99          50          49          

   Yes                                71          2           49         **0.012**

  Pathologic T classification                                             

   pTx/pTis                           14          7           7           

   pT1                                26          13          13          

   pT2                                75          39          36          

   pT3                                18          7           11          

   pT4                                37          6           31         **0.007**

  Pathologic N classification                                             

   pN0                                20          14          6           

   pN1                                63          29          34          

   pN2                                52          16          36          

   pN3                                35          13          22         **0.02**

  Downstage                                                               

   No                                 115         43          72          

   Yes                                55          29          26         0.07

  Histology                                                               

   Ductal invasive                    118         55          63          

   Lobular invasive                   36          12          24          

   Others                             16          5           11         0.24

  Pathologic skin involvement                                             

   Absent                             136         66          70          

   Present                            34          6           28         **0.001**

  Extracapsular extension                                                 

   Absent                             115         52          63          

   Present                            55          20          35         0.32

  LVI                                                                     

   Absent                             101         47          54          

   Present                            69          25          44         0.21

  Nuclear grading∗                                                        

   G1                                 11          6           5           

   G2                                 54          26          28          

   G3                                 80          33          47         0.58

  Ki 67 index                                                             

   \<20                               117         53          64          

   ≥20                                53          19          34         0.32

  ER status                                                               

   Negative                           64          30          34          

   Positive                           106         42          64         0.42

  PgR status                                                              

   Negative                           83          40          43          

   Positive                           87          32          55         0.16

  NAC regimen                                                             

   Anthracyclines-based               69          27          42          

   Anthracyclines and taxanes-based   93          44          49          

   No anthracyclines                  8           1           7          0.13

  Adjuvant hormonal therapy                                               

   No                                 62          28          34          

   Tamoxifen                          75          31          44          

   AIs                                33          13          20         0.89
  -----------------------------------------------------------------------------------

\*Some data are missing; °*P* value from Fisher exact test or chi-square for trend, as appropriate.

PMRT: postmastectomy radiotherapy; LVI: lymphovascular invasion; ER: estrogen receptors; PgR: progesterone receptors; NAC: neoadjuvant chemotherapy; AIs: aromatase inhibitors.

###### 

Locoregional recurrence, distant metastases, and overall survival rates according to clinical factors.

  Variable                             Patient   Overall survival   LRR free survival   DM free survival                    
  ------------------------------------ --------- ------------------ ------------------- ------------------ ----------- ---- -----------
  Age groups                                                                                                                 
   ≤40                                 33        16                                     6                              20    
   41--50                              62        24                                     9                              20    
   51--60                              5         20                                     9                              25    
   \>60                                25        12                 0.73                2                  0.74        13   0.67
  Clinical T                                                                                                                 
   T1                                  4         3                                      0                              3     
   T2                                  52        15                                     3                              18    
   T3                                  48        17                                     9                              25    
   T4                                  66        37                 0.09                14                 0.28        40   0.12
  Clinical N                                                                                                                 
   N0                                  42        14                                     5                              15    
   N1                                  95        39                                     11                             49    
   N2                                  33        19                 0.15                10                 **0.034**   22   **0.028**
  Clinical stage                                                                                                             
   IIA                                 16        5                                      0                              5     
   IIB                                 51        17                                     6                              21    
   IIIA                                35        13                                     6                              20    
   IIIB                                63        36                                     14                             39    
   IIIC                                3         1                  0.15                0                  0.19        1    0.09
  Multiple Foci                                                                                                              
   No                                  99        40                                     18                             46    
   Yes                                 71        32                 0.60                8                  0.28        40   0.19
  Downstage                                                                                                                  
   No                                  115       50                                     19                             64    
   Yes                                 55        22                 0.34                7                  0.31        22   **0.029**
  PMRT                                                                                                                       
   No                                  72        31                                     12                             36    
   Yes                                 98        41                 0.83                14                 0.57        50   0.93
  PMRT volumes                                                                                                               
   Chest wall                          14        5                                      1                              5     
   Chest wall + SC                     74        34                 0.35                12                 0.38        43   0.11
  NAC regimen                                                                                                                
   Anthracyclines-based                69        35                                     14                             41    
   Anthracyclines- and taxanes-based   93        33                                     10                             41    
   No anthracyclines                   8         4                  0.25                2                  0.29        4    0.16
  Adjuvant hormonal therapy                                                                                                  
   No                                  62        34                                     10                             35    
   Tamoxifen                           75        28                                     11                             34    
   AIs                                 33        10                 0.11                5                  0.93        17   0.31
                                                                                                                            
  Total                                170       72                                     26                             86    

LRR: locoregional recurrence; DM: distant metastases; PMRT: postmastectomy radiotherapy; NAC: neoadjuvant chemotherapy; SC: supraclavicular nodal region; AIs: aromatase inhibitors.

###### 

Locoregional recurrence, distant metastases, and overall survival rates according to pathologic factors.

  Variable                      Patient   Overall survival   LRR free survival   DM free survival                    
  ----------------------------- --------- ------------------ ------------------- ------------------ ----------- ---- ------------
  Multiple foci                                                                                                       
   No                           99        40                                     18                             46    
   Yes                          71        32                 0.60                8                  0.28        40   0.19
  Pathologic T                                                                                                        
   pTx/pTis                     14        8                                      3                              8     
   pT1                          26        5                                      0                              7     
   pT2                          75        29                                     8                              38    
   pT3                          18        10                                     5                              11    
   pT4                          37        20                 **0.04**            10                 **0.015**   22   0.13
  Pathologic N                                                                                                        
   pN0                          20        3                                      2                              3     
   pN1                          63        27                                     9                              28    
   pN2                          52        26                                     12                             33    
   pN3                          35        16                 **0.026**           3                  0.12        22   **0.0002**
  Stage                                                                                                               
   0                            3         2                                      1                              2     
   I                            6         0                                      0                              0     
   IIa                          25        7                                      3                              7     
   IIb                          25        9                                      4                              9     
   IIIa                         43        20                                     6                              27    
   IIIb                         39        18                                     8                              21    
   IIIc                         29        16                 **0.049**           4                  0.76        20   **0.0006**
  Histology                                                                                                           
   Ductal invasive              118       52                                     19                             59    
   Lobular invasive             36        13                                     1                              19    
   Others                       16        7                  0.85                6                  **0.008**   8    0.94
  Pathologic skin involvement                                                                                         
   Absent                       136       56                                     16                             67    
   Present                      34        16                 0.78                10                 **0.018**   19   0.83
  LVI                                                                                                                 
   Absent                       101       38                                     14                             44    
   Present                      69        34                 0.19                12                 0.35        42   **0.044**
  Nuclear grading∗                                                                                                    
   G1                           11        4                                      0                              5     
   G2                           54        17                                     3                              25    
   G3                           80        40                 0.18                16                 **0.024**   44   0.52
  Ki 67 index                                                                                                         
   \<20                         117       48                                     21                             57    
   ≥20                          53        24                 0.15                5                  0.34        29   0.09
  ER status                                                                                                           
   Negative                     64        35                                     10                             37    
   Positive                     106       37                 **0.015**           16                 0.99        49   0.20
  PgR status                                                                                                          
   Negative                     83        36                                     13                             41    
   Positive                     87        36                 0.83                13                 0.87        45   0.83
  Extracapsular extension                                                                                             
   Absence                      115       37                                     13                             48    
   Presence                     55        35                 **0.0007**          13                 **0.035**   38   0.003
                                                                                                                     
  Total                         170       72                                     26                             86    

\*Some data are missing.

LRR: locoregional recurrence; DM: distant metastases; PMRT: postmastectomy radiotherapy; LVI: lymph vascular invasion; ER: estrogen receptors; PgR: progesterone receptors.

###### 

Multivariate analysis of distant metastases occurrence and overall survival.

  Factor                                Hazard ratio   95% confidence interval   *P* value
  ------------------------------------- -------------- ------------------------- -----------
  Distant metastases                                                              
   pN2                                  6.95           2.11--22.56               0.007
   pN3                                  7.21           2.15--24.18               0.009
   Extracapsular extension              1.91           1.25--2.92                0.023
  Overall survival                                                                
   pN2                                  5.00           1.51--16.52               0.035
   pN3                                  4.50           1.31--15.48               0.037
   Extracapsular extension              2.18           1.37--3.46                0.009
   Estrogen receptor positive disease   0.57           0.36--0.90                0.003

###### 

Locoregional recurrence-free survival rate according to postmastectomy radiotherapy.

  Feature                              *N*   No PMRT   PMRT   LRR   *P* value   
  ------------------------------------ ----- --------- ------ ----- ----------- -----------
  Age groups                                                                     
   ≤40                                 33    18        15     5     1           0.13
   41--50                              62    25        37     4     5           0.53
   51--60                              5     18        32     3     6           0.62
   \>60                                25    11        14     0     2           0.24
  Clinical T                                                                     
   T1                                  4     2         2      0     0           ---
   T2                                  52    26        24     3     0           0.12
   T3                                  48    27        21     8     1           **0.015**
   T4                                  66    15        51     1     13          0.15
  Clinical N                                                                     
   N0                                  42    20        22     3     2           0.64
   N1                                  95    45        90     7     4           0.15
   N2                                  33    7         26     2     8           0.87
  Multiple foci                                                                  
   No                                  99    50        49     1     7           0.27
   Yes                                 71    22        49     1     7           0.26
  Pathologic T                                                                   
   pTx/pTis                            14    7         7      2     1           0.29
   pT1                                 26    13        13     0     0           ---
   pT2                                 75    39        36     6     3           0.10
   pT3                                 18    7         11     3     2           0.18
   pT4                                 37    6         31     1     9           0.49
  Pathologic N                                                                   
   pN0                                 20    14        6      2     0           0.35
   pN1                                 63    29        34     3     6           0.62
   pN2                                 52    16        36     5     7           0.16
   pN3                                 35    13        22     2     1           0.54
  Downstage                                                                      
   No                                  115   43        72     8     11          0.51
   Yes                                 55    29        26     4     3           0.68
  Histology                                                                      
   Ductal invasive                     118   55        63     9     10          0.78
   Lobular invasive                    36    12        24     0     1           0.48
   Others                              16    5         11     3     3           0.17
  Pathologic skin involvement                                                    
   Absent                              136   66        70     11    5           0.061
   Present                             34    6         28     1     9           0.44
  LVI                                                                            
   Absent                              101   47        54     8     6           0.32
   Present                             69    25        44     4     8           0.93
  Nuclear grading∗                                                               
   G1                                  11    6         5      0     0           ---
   G2                                  54    26        28     3     0           0.06
   G3                                  80    33        47     7     9           0.86
  Ki 67 index                                                                    
   \<20                                117   53        64     10    11          0.76
   ≥20                                 53    19        34     2     3           0.69
  ER status                                                                      
   Negative                            64    30        34     4     6           0.81
   Positive                            106   42        64     8     8           0.32
  PgR status                                                                     
   Negative                            83    40        43     6     7           0.93
   Positive                            87    32        65     6     7           0.39
  Extracapsular extension                                                        
   Absence                             115   52        63     8     5           0.20
   Presence                            55    20        35     4     9           0.89
  NAC regimen                                                                    
   Anthracyclines-based                69    27        42     5     9           0.74
   Anthracyclines- and taxanes-based   93    44        49     6     4           0.38
   No anthracyclines-based             8     1         7      1     1           **0.008**
  Adjuvant hormonal therapy                                                      
   No                                  62    28        34     4     6           0.86
   Tamoxifen                           75    31        44     5     6           0.71
   AIs                                 33    13        20     3     2           0.32
                                                                                
  Total                                170   72        98     12    14           

\*Some data are missing. LRR: locoregional recurrence; PMRT: postmastectomy radiotherapy; LVI: lymph vascular invasion; ER: estrogen receptors; PgR: progesterone receptors; NAC: neoadjuvant chemotherapy; AIs: aromatase inhibitors.

###### 

Main chemotherapy- and radiotherapy-related adverse events.

                                                                  *N*   \%
  --------------------------------------------------------------- ----- ----
  *Chemotherapy-related side effects*                                    
  Anemia                                                                 
   Grades 0--2                                                    150   88
   Grades 3--5                                                    20    12
  Neutropenia                                                            
   Grades 0--2                                                    142   83
   Grades 3--5                                                    28    17
  Piastrinopenia                                                         
   Grades 0--2                                                    150   88
   Grades 3--5                                                    20    20
  Mucositis                                                              
   Grades 0--2                                                    158   93
   Grades 3--5                                                    12    7
  Alopecia                                                        162   95
  Hypertransaminasemia                                            15    9
  Febrile neutropenia                                             5     3
  *Ra* *di* *ot* *he* *ra* *py*-*related*   *side*   *effects*°          
  Erythema                                                        32    33
  Thoracic wall pain                                              25    25
  Edema                                                           3     3
  Fatigue                                                         30    30
  Fibrosis                                                        20    20
  Telangiectasia                                                  8     8

°PMRT group, any grades.
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